Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Curated subset. The full adverse-effect list is in the TGA Product Information; click any citation above to open it.
“Lutetium ( 177 Lu) oxodotreotide has a high affinity for subtype 2 somatostatin receptors (SST 2 ). It binds to malignant cells which express SST 2 .”
“The mean terminal blood elimination half-life is 71 (±28) hours for lutetium ( 177 Lu) oxodotreotide.”
“In vitro drug interaction studies performed with non-radioactive lutetium ( 175 Lu) oxodotreotide showed an absence of significant inhibitory or induction effects on human CYP450 enzymes (CYP1A2, 2B6, 2C9, 2C19 or 2D6), no potential interactions with P- glycoprotein (efflux transporter), as well as OAT1, OAT3, OCT1, OCT2, OATP1B1, OATP1B3, and BCRP transporters.”
Working under the parallel aged-care framework? Aged-care equivalent →